Glenmark Pharmaceuticals’ arm signs license agreement with Jiangsu Alphamab, 3DMed

25 Jan 2024 Evaluate

Glenmark Pharmaceuticals’ subsidiary -- Glenmark Specialty S.A. (GSSA) has signed a license agreement with Jiangsu Alphamab Biopharmaceuticals Co., (Jiangsu Alphamab) and 3D Medicines (BEIJING) Co., (3DMed), (together as the Licensors), for KN035 (Envafolimab) for India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America (the Territory).

Under the terms of the agreement, GSSA will receive from Jiangsu Alphamab and 3DMed, an exclusive license to develop, register, commercialize, Envafolimab for the oncology indication in the Territory. Jiangsu Alphamab will be the exclusive supplier of the product. Jiangsu Alphamab (on behalf of the Licensors) will receive a low double digit Million US Dollar amount up to launch, additional triple digit Million US Dollar milestone payments based on sales performance across the length of the agreement, and a royalty fee of single-to-double-digits percentage according to the level of net sales.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. 


Glenmark Pharma Share Price

1465.30 -27.05 (-1.81%)
21-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Dr. Reddys Lab 1194.55
Cipla 1465.65
Lupin 2043.30
Torrent Pharma 3104.55
Abbott India 27145.25
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.